WebThis presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform ... (NHL) CA-4948* IRAK4 IRAK4L-expressing Leukemia (AML/MDS) Fimepinostat HDAC/PI3K MYC-altered ... In Nov 2024, the NCI selected CA-4948, Curis’s first-in ... WebJan 27, 2024 · The most advanced and currently promising is named CA-4948 for the treatment of Non-Hodgkin’s Lymphoma (“NHL”), Acute Myeloid Leukemia (“AML”), and Myelodysplastic Syndromes (“MDS”). I believe...
Curis Announces Updated Preliminary Data from Ongoing Phase 1 …
WebMay 21, 2024 · May 11, 2015 Garret Hohl NHL Topical Analysis Tags: Calgary Flames, Colorado Avalanche, Corsi, Fenwick, Mark Giordano, Paul Stastny, Penalty Kill, Possession, Powerplay, Scoring Chances 3 Comments. Odds are, a team that performs like the 2014-2015 Calgary Flames in shots, possession, and chances will miss the playoffs. WebNov 13, 2024 · A phase 1 trial in patients with NHL is being conducted to determine safety, pharmacokinetics, and preliminary efficacy of CA-4948 as monotherapy. Patients and Methods. At the 18-Jul-2024 data cut-off date, 22 patients have been treated with single-agent CA-4948. incase macbook pro 17
Curis Announces Updated Preliminary Data from Ongoing Phase 1 …
WebCA-4948 in patients expressing IRAK4-L •Capitalize on unique clinical experience with VISTA by in-licensing the leading monoclonal antibody program (CI-8993) and initiating a Ph1 study in solid tumors 2024 2024 2024 Initial Clinical Data Report preliminary efficacy data for CA-4948 Ph1 study in NHL Evaluate new published research in WebCA-4948 is the first clinical candidate targeting IRAK4 to be evaluated in cancer patients. Here we present Phase I results of CA-4948 in patients with relapsed/refractory hematologic malignancies. Method CA-4948-101 is a phase I trial dose escalation trial with a … WebNov 5, 2024 · Introduction. CA-4948 is a novel oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is part of the Myddosome signaling pathway, and is essential for signaling downstream of toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family in immune cells including B lymphocytes. . inclusive teaching means